GS-9973 (Synonyms: GS-9973) |
Catalog No.GC16430 |
Le GS-9973 (GS-9973) est un inhibiteur Syk sélectif biodisponible par voie orale avec une IC50 de 7,7 nM.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1229208-44-9
Sample solution is provided at 25 µL, 10mM.
GS-9973 is a selective inhibitor of Syk with IC50 value of 7.7 nM [1].
Spleen tyrosine kinase (Syk) is a cytoplasmic tyrosine kinase that is expressed mainly in hematopoietic cells and acts as a mediator of immunoreceptor signaling. Syk can be used for therapy of autoimmune, oncology indications and allergy [1].
GS-9973 is an orally bioavailable and selective Syk inhibitor. GS-9973 showed good absorption potential and high bioavailability. In monocytes, GS-9973 inhibited immune-complex-stimulated cytokine production and BCR-mediated proliferation and activation of B-cells [1]. In chronic lymphocytic leukemia (CLL) cells, GS-9973 significantly reduced pAkt and ribosomal S6 phosphorylation. These results suggested that GS-9973 inhibited B-cell receptor (BCR) mediated signaling pathways. In CLL samples, the combination of GS-9973 and idelalisib synergistically reduced CLL cell viability [2].
In chronic lymphocytic leukemia patients, GS-9973 inhibited adenopathy and reduced lymph node [3].
References:
[1]. Currie KS, Kropf JE, Lee T, et al. Discovery of GS-9973, a selective and orally efficacious inhibitor of spleen tyrosine kinase. J Med Chem, 2014, 57(9): 3856-3873.
[2]. Burke RT1, Meadows S, Loriaux MM, et al. A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor. Oncotarget, 2014, 5(4): 908-915.
[3]. Sharman J, Hawkins M, Kolibaba K, et al. An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia. Blood, 2015, 125(15): 2336-2343.
Average Rating: 5
(Based on Reviews and 25 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *